

## TELEFACSIMILE LETTER FROM

**Jones Day**  
222 East 41<sup>st</sup> Street  
New York, New York 10017  
Telephone Number (212) 326-3939  
Fax Nos.: (212) 755-7306

To: WOODWARD, Cherie Michelle

Fax No.: (571) 273-3329

From: Laura A. Coruzzi

Pages: 8

Date: February 3, 2009

Application of: Brines *et al.*

Confirmation No.: 7619

Serial No.: 10/520,140

Art Unit: 1647

Filed: January 3, 2005

Examiner: WOODWARD, Cherie Michelle

For: TISSUE PROTECTIVE CYTOKINES FOR THE  
PROTECTION, RESTORATION, AND  
ENHANCEMENT TO RESPONSE CELLS

Attorney Dock et No: 10165-037-999  
(Formerly: KW00-2B02-US)

Please find attached a claim set regarding the above-identified patent application in preparation of our in-person interview on February 4, 2009.

**Proposed Claim Amendments For Discussion Purposes During the  
Interview of February 4, 2009**

1. (Withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a tissue protective cytokine; at least one anti-inflammatory agent; and a pharmaceutically acceptable carrier.
2. (Withdrawn) The pharmaceutical composition of claim 1, wherein the anti-inflammatory agent is selected from the group consisting of corticosteroids, glucocorticoids, steroids, non-steroidal anti-inflammatory drugs, beta-agonists, anticholinergic agents, methyl xanthines, gold injections, sulphasalazine, penicillamine, anti-angiogenic agents, dapsone, psoralens, anti-malarial agents, anti-viral agents, and antibiotics.
3. (Withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a tissue protective cytokine; at least one immunomodulatory agent; and a pharmaceutically acceptable carrier.
4. (Withdrawn) The pharmaceutical composition of claim 3, wherein the immunomodulatory agent is selected from the group consisting of methothrexate, leflunomide, cyclophosphamide, cytoxan, Immuran, cyclosporine A, minocycline, azathioprine, antibiotics, methylprednisolone, corticosteroids, steroids, mycophenolate mofetil, rapamycin, mizoribine, deoxyspergualin, brequinar, malononitriloamides, T cell receptor modulators, and cytokine receptor modulators.
5. (Withdrawn) A pharmaceutical composition of claim 1 or 3, wherein said tissue protective cytokine is selected from the group consisting of i) an erythropoietin that lacks sialic acid moieties; ii) an erythropoietin that lacks N-linked or lacks O-linked carbohydrates; iii) an erythropoietin having a reduced carbohydrate content by treatment of native erythropoietin with at least one glycosidase; iv) an erythropoietin having at least one or more oxidized carbohydrates; v) an erythropoietin comprising at least one or more oxidized carbohydrates which is chemically reduced; vi) an erythropoietin comprising at least one or more modified arginine residues; vii) an erythropoietin comprising at least one or more modified lysine residues or a modification of the N-terminal amino group of the erythropoietin molecule; viii) an erythropoietin comprising at least a modified tyrosine residue; ix) an erythropoietin comprising at least a modified aspartic acid or a glutamic acid residue; x) an erythropoietin comprising at least a modified tryptophan residue; xi) an erythropoietin having at least one amino group removed; xii) an erythropoietin comprising at

least an opening of at least one of the cystine linkages in the erythropoietin molecule; and  
xiii) a truncated erythropoietin.

6. (Canceled).

7. (Canceled).

8. (Currently amended) A method for treating an inflammatory disease in a mammal comprising responsive cells, said method comprising

(a) administering to a mammal in need thereof a pharmaceutical composition comprising a prophylactically or therapeutically effective amount of ~~an~~ one or more of the chemically modified erythropoietins listed under having at least one of the modifications (i) to (v) below, wherein said modified erythropoietin has a reduced level of in vivo erythropoietic activity compared to native erythropoietin as determined by the exhypoxic polycythemic mouse bioassay, and has tissue protective activity in vivo as determined by the middle cerebral artery occlusion test

i) one or more chemically modified arginine residues;

ii) one or more chemically modified lysine residues or a modification of the N-terminalamino group;

iii) one or more chemically modified tyrosine residues;

iv) one or more chemically modified aspartic acid or a glutamic acid residues;  
and

v) one or more chemically modified tryptophan residues;

and

(b) administering to the mammal a prophylactically or therapeutically effective amount of one or more anti-inflammatory agents or immunomodulatory agents.

9. (Previously presented) The method of claim 8, wherein the anti-inflammatory agent is selected from the group consisting of a corticosteroid, a glucocorticoid, a steroid, a non-steroidal anti-inflammatory drug, a beta-agonist, an anticholinergic agent, a methyl xanthine, gold injection, a sulphasalazine, penicillamine, an anti-angiogenic agent, dapsone, psoralen, an anti-malarial agent, an anti-viral agent, and an antibiotic.

10. (Original) The method of claim 8, wherein the immunomodulatory agent is selected from the group consisting of a proteinaceous agent, a peptide mimetic, an

antibody, a nucleic acid molecule, a small molecule, an organic compound, an inorganic compound, methothrexate, leflunomide, cyclophosphamide, cytoxan, Immuran, cyclosporine A, minocycline, azathioprine, an antibiotic, methylprednisolone (MP), a corticosteroid, a steroid, mycophenolate mofetil, rapamycin, mizoribine, deoxyspergualin, brequinar, a malononitriloamidine, a T cell receptor modulator, and a cytokine receptor modulator.

11. (Canceled)

12. (Previously presented) The method of claim 8, wherein said erythropoietin is asialoerythropoietin or phenylglyoxal-erythropoietin.

13. (Previously presented) The method of claim 8, wherein erythropoietin is capable of traversing an endothelial cell barrier.

14. (Original) The method of claim 13, wherein the endothelial cell barrier is selected from the group consisting of blood-brain barrier, blood-eye barrier, blood-testis barrier, blood-ovary barrier, and blood-uterus barrier.

15. (Previously presented) The method of claim 8, wherein the responsive cells are selected from the group consisting of neuronal cells, muscle cells, heart, lung, liver, kidney, small intestine, adrenal cortex, adrenal medulla, capillary cells, endothelial cells, testes, ovary, endometrial cells, and stem cells.

16. (Previously presented) The method of claim 8, wherein the responsive cells further comprise cells selected from the group consisting of photoreceptor cells, ganglion cells, bipolar cells, horizontal cells, amacrine cells, Müller cells, myocardium cells, pace maker cells, sinoatrial node cells, sinus node cells, atrioventricular node cells, bundle of His cells, hepatocyte cells, stellate cells, Kupffer cells, mesangial cells, goblet cells, intestinal gland cells, enteral endocrine cells, glomerulosa cells, fasciculate cells, reticularis cells, chromaffin cells, pericyte cells, Leydig cells, Sertoli cells, sperm cells, Graffian follicle cells, primordial follicle cells, endometrial stroma cells, and endometrial cells.

17.- 23. (Canceled)

24. (Previously presented) The method of claim 8, wherein said erythropoietin is an erythropoietin comprising a R-glyoxal moiety on the one or more arginine residues, wherein R is aryl or alkyl moiety.

25. (Previously presented) The method of claim 24, wherein said erythropoietin is phenylglyoxal-erythropoietin.

26. (Previously presented) The method of claim 8, wherein said erythropoietin is an erythropoietin in which at least one arginine residue is modified by reaction with a vicinal diketone selected from the group consisting of 2,3-butanedione and cyclohexanedione.

27. (Previously presented) The method of claim 8, wherein said erythropoietin is an erythropoietin in which at least one arginine residue is reacted with 3-deoxyglucosone.

28. (Previously presented) The method of claim 8, wherein said erythropoietin is an erythropoietin molecule comprising at least one biotinylated lysine or biotinylated N-terminal amino group.

29. (Previously presented) The method of claim 8, wherein said erythropoietin molecule is biotinylated.

30. (Previously presented) The method of claim 8, wherein said erythropoietin is a glucitolyl lysine erythropoietin or a fructosyl lysine erythropoietin.

31. (Previously presented) The method of claim 8, wherein said erythropoietin is an erythropoietin having at least one carbamylated lysine residue.

32. (Previously presented) The method of claim 31, wherein said carbamylated erythropoietin is selected from the group consisting of alpha-N-carbamoylerythropoietin; N-epsilon-carbamoylerythropoietin; alpha-N-carbamoyl, N-epsilon-carbamoylerythropoietin; alpha-N-carbamoylasialocerythropoietin; N-epsilon-carbamoylasialoerythropoietin; alpha-N-carbamoyl, N-epsilon-carbamoylasialoerythropoietin; alpha-N-carbamoylhyposialocerythropoietin; N-epsilon-carbamoylhyposialoerythropoietin; and alpha-N-carbamoyl, N-epsilon-carbamoylhyposialoerythropoietin.

33. (Previously presented) The method of claim 8, wherein said erythropoietin is an erythropoietin in which at least one lysine residue is acylated.

34. (Previously presented) The method of claim 33, wherein a lysine residue of said erythropoietin is acetylated.

35. (Original) The method of claim 34, wherein said acetylated erythropoietin is selected from the group consisting of alpha-N-acetylerythropoietin; N-epsilon-acetylerythropoietin; alpha-N-acetyl, N-epsilon-acetylerythropoietin; alpha-N-

acetylasialoerythropoietin; N-epsilon- acetylasialoerythropoietin; alpha-N-acetyl, N-epsilon-acetylasialoerythropoietin; alpha-N-acetylhyposialoerythropoietin; N-epsilon-acetylhyposialoerythropoietin; and alpha-N-acetyl, N-epsilon-acetylhyposialoerythropoietin.

36. (Previously presented) The method of claim 8, wherein said erythropoietin is an erythropoietin comprising a succinylated lysine residue.

37. (Previously presented) The method of claim 36, where said erythropoietin is selected from the group consisting of alpha-N-succinylerythropoietin; N-epsilon-succinylerythropoietin; alpha-N-succinyl, N-epsilon-succinylerythropoietin; alpha-N-succinylasialoerythropoietin; N-epsilon-succinylasialoerythropoietin; alpha-N-succinyl, N-epsilon-succinylasialoerythropoietin; alpha-N-succinylhyposialoerythropoietin; N-epsilon-succinylhyposialoerythropoietin; and alpha-N-succinyl, N-epsilon-succinylhyposialoerythropoietin.

38. (Previously presented) The method of claim 8, wherein said erythropoietin is an erythropoietin with at least one lysine residue modified by a 2, 4, 6-trinitrobenzenesulfonic acid salt.

39. (Previously presented) The method of claim 38, wherein the salt is 2, 4, 6-trinitrobenzenesulfonate sodium.

40. (Previously presented) The method of claim 8, wherein said erythropoietin is an erythropoietin in which at least one tyrosine residue is nitrated and/or iodinated.

41. (Previously presented) The method of claim 8, wherein said erythropoietin is an erythropoietin in which an aspartic acid and/or glutamic acid residue is reacted with a carbodiimide followed by reaction with an amine.

42. (Original) The method of claim 41, wherein said amine is glycynamide.

43. (Previously presented) The method of claim 8, wherein the inflammatory disease results from a disease condition or trauma.

44. (Previously presented) The method of claim 8, wherein the inflammation is selected from the group consisting of angitis, chronic bronchitis, pancreatitis, osteomyelitis, rheumatoid arthritis, glomerulonephritis, optic neuritis, temporal arteritis, encephalitis, meningitis, transverse myelitis, dermatomyositis, polymyositis, necrotizing fasciitis, hepatitis, and necrotizing enterocolitis.

45. (Previously presented) The method of claim 8, wherein the erythropoietin inhibits inflammation resulting from cytokines produced by glial cells.

46. (Previously presented) The method of claim 8, wherein the inflammation is triggered by apoptosis.

47-52. (Cancelled).

53. (Previously presented) The method of claim 8, wherein said erythropoietin is an alpha-N-carbamoyl, N-epsilon-carbamoylerythropoietin.

54. (Previously presented) The method of claim 8, wherein said erythropoietin is non-erythropoietic.

55. (Previously presented) The method of claim 8, wherein the erythropoietin and the anti-inflammatory agent or immunomodulatory agent are administered to the mammal concurrently.